person

Luís T. B.

Country
Portugal
Department
Allergology

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
0
Sites with multiple studies

Has run more than one trial at 0 of 12 partner sites.

Specializations

Atrial Fibrillation and Stroke Prevention

Investigates therapeutic strategies for Atrial Fibrillation to reduce thromboembolic risk. Emphasizes prevention of stroke in high‑risk populations.

  • Milvexian comparative efficacy versus apixaban
  • Asundexian efficacy for stroke prevention
  • Thromboembolic risk reduction strategies

Evaluates bleeding risk with novel oral anticoagulants like milvexian.

Acute Coronary Syndrome and Myocardial Infarction

Focuses on management of Acute Coronary Syndrome. Targets reduction of post‑myocardial infarction major adverse cardiovascular events.

  • Milvexian post‑MI cardiovascular outcomes
  • Cardioembolic event reduction
  • Antiplatelet adjunctive therapy

Studies comparative efficacy of apixaban in acute coronary settings.

Heart Failure Therapeutics

Explores interventions for Heart Failure with preserved ejection fraction. Evaluates impact on cardiovascular death and rehospitalization.

  • Finerenone effect on HFmrEF/HFpEF
  • Hospitalization reduction endpoints
  • Renal modulation in heart failure

Investigates renal‑modulating agent finerenone for HF outcomes.

Allergic Rhinitis and Asthma Immunotherapy

Advances treatment of moderate‑to‑severe allergic rhinitis. Addresses comorbid allergic asthma using allergen‑specific immunotherapy.

  • Mannan‑conjugated allergoids for house dust mite allergy
  • EP‑088_MM09 subcutaneous immunotherapy
  • Dermatophagoides allergen targeting

Utilizes mannan‑conjugated allergoids for house dust mite allergy.

Ischemic Stroke and Transient Ischemic Attack

Addresses secondary prevention after Acute Ischemic Stroke. Includes high‑risk Transient Ischemic Attack management.

  • Milvexian post‑stroke anticoagulation
  • Stroke risk reduction versus placebo
  • Non‑inferiority assessment of new agents

Assesses non‑inferiority of asundexian to standard therapy.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.